We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Arcellx, Inc. (ACLX - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arcellx, Inc. is one of 890 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Arcellx, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ACLX's full-year earnings has moved 1.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ACLX has returned 76.4% so far this year. Meanwhile, stocks in the Medical group have lost about 8% on average. This means that Arcellx, Inc. is outperforming the sector as a whole this year.
Astellas Pharma Inc. (ALPMY - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 16.1%.
Over the past three months, Astellas Pharma Inc.'s consensus EPS estimate for the current year has increased 15.2%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Arcellx, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 435 individual stocks and currently sits at #94 in the Zacks Industry Rank. On average, this group has lost an average of 0.7% so far this year, meaning that ACLX is performing better in terms of year-to-date returns.
On the other hand, Astellas Pharma Inc. belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #78. The industry has moved -0.8% year to date.
Arcellx, Inc. and Astellas Pharma Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Arcellx, Inc. (ACLX - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arcellx, Inc. is one of 890 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Arcellx, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ACLX's full-year earnings has moved 1.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ACLX has returned 76.4% so far this year. Meanwhile, stocks in the Medical group have lost about 8% on average. This means that Arcellx, Inc. is outperforming the sector as a whole this year.
Astellas Pharma Inc. (ALPMY - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 16.1%.
Over the past three months, Astellas Pharma Inc.'s consensus EPS estimate for the current year has increased 15.2%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Arcellx, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 435 individual stocks and currently sits at #94 in the Zacks Industry Rank. On average, this group has lost an average of 0.7% so far this year, meaning that ACLX is performing better in terms of year-to-date returns.
On the other hand, Astellas Pharma Inc. belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #78. The industry has moved -0.8% year to date.
Arcellx, Inc. and Astellas Pharma Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.